Under the terms of the agreement, Gilead will provide an upfront payment of $10 million. Additionally, Hookipa will be eligible to receive milestone payments based upon the achievement
This new funding will enable the company to finance the two first Phase II clinical trial of its EYP001 asset in both chronic hepatitis B (HBV) and NASH.
The first investigational product, LBL100 (3% bupivacaine in Lipogel), is being developed as a long-acting local anesthetic for post-operative pain. Virpax expects to file a Pre-Investigational New Drug
High risk of recurrence is defined as lymph node-positive or hormone receptor-negative disease. The Perjeta-based regimen should be administered for a total of one year (up to 18
MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced
The approval is for a 2mg dose of the drug in adult patients who did not show adequate response to one or more tumor necrosis factor (TNF) inhibitor
The partnership will assess the safety and efficacy of Nektar's NKTR-214, a CD122-biased agonist, in combination with entinostat, Syndax's oral, small molecule Class 1 specific HDAC inhibitor, in
Researchers want to discover whether AstraZeneca and MSD’s experimental medicine, selumetinib (AZD6244, ARRY-142886), can be effective in combination with dexamethasone, a treatment already used for several conditions including
The planned start of the Phase 1b/2 study (68284528MMY2001), scheduled to begin enrollment in the second half of 2018, follows the US Food and Drug Administration (FDA) clearance
The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations. This news follows the announcement earlier this month that the first pivotal Phase III
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.